Delivery Order SPE2DB20D2001-SPE2DB20FM30W
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order worth $4,722.50 from the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of various pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and other critical care items. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award to Amerisourcebergen Drug Corp (a subsidiary of Cencora, Inc.) is a Delivery Order worth $1,311.38 for "PRIME VENDOR PHARM BRANCH-PHILADELPHIA" from the Defense Logistics Agency (DLA). The contract is a Firm Fixed Price arrangement with no set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as the...
- This federal contract award is for a Prime Vendor Pharmaceutical Branch in Philadelphia, awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The delivery order is a firm fixed-price contract valued at $2,337.72, with a performance period through April 16, 2021. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order for pharmaceutical and medical supplies valued at $1,854.39. The award was issued by the Defense Logistics Agency (DLA) and supports the Prime Vendor Pharmaceutical Branch in Philadelphia. The contract is a firm-fixed-price delivery order with no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order (SPE2DX24FG775) valued at $3,395.24 with a period of performance ending on February 22, 2024. The contract was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency, for the delivery of pharmaceutical products and medical supplies. Amerisourcebergen has a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $1,044.96 issued by the Defense Logistics Agency (DLA) Troop Support Medical. The contract covers the provision of various pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas. Amerisourcebergen holds a significant Indefinite Delivery Contract...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $1,111.20 from the Defense Logistics Agency (DLA) for pharmaceutical branch support services in Philadelphia. The contract is a firm-fixed-price arrangement with no set-aside designation, indicating open competition. As a major pharmaceutical distributor, Amerisourcebergen has established itself as a key vendor for federal healthcare programs, particularly within military...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $9,331.21 for pharmaceutical and medical supply products. The contract was awarded by the Defense Logistics Agency (DLA) and has no set-aside designation, indicating full and open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the...
- This federal contract award to Amerisourcebergen Drug Corp (a subsidiary of Cencora, Inc.) is a Delivery Order valued at $9,329.76, awarded by the Defense Logistics Agency (DLA) for pharmaceutical products and medical supplies. The contract has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $3,530.51 issued by the Defense Logistics Agency (DLA) Troop Support Medical. The contract covers the supply of a wide range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas. Amerisourcebergen holds a significant Indefinite Delivery Contract...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB20FM30WDelivery Order
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $50,327.73 for pharmaceutical and medical supplies. The contract was awarded by the Defense Logistics Agency (DLA) for the Prime Vendor Pharmaceutical Branch in Philadelphia. The contract is a Firm Fixed Price Delivery Order that does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military healthcare programs globally. Amerisourcebergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $50.3k | 8/17/20 |